Oncostellae’s R&D projects were initiated using private funds provided by the founders and a subvention granted by the Galician Agency for Innovation (GAIN) and the European Union (ERDF) for the development of the project Oncogalfarma within the framework Conecta Peme 2014/15.
In 2015 Inveready entered the company as a financial partner.


Project in collaboration with Galchimia, Nanogap, AMSLAB and several researcher groups from University of Santiago de Compostela (USC), The Health Research Institute of Santiago de Compostela (IDIS) and LEITAT with the objective:
Found new treatments for cancer with the Development of therapies aimed at different therapeutic targets and combined treatments.
This project is granted by the Agencia Gallega de Innovación (GAIN) througth the Conecta Pyme program, co-financied by European Regional Development Fund (ERDF) and supported by the Consellería de Economía, Empleo e Industria (Xunta de Galicia).

Budget Oncostellae: 237.577,91 €

Budget Neogalfarm: 1.076.339,63 €


Oncostellae is supported by ENISA (a public institution that finances new and innovative projects) and co-financied by the European Regional Development Fund: "A way to build Europe".


Project in collaboration with the companies AMSLAB and Galchimia with the objective: “Development of new complementary therapies for the treatment of oncological diseases”.
This project was co-financed by the European Regional Development Fund (ERDF) and the Xunta de Galicia (Conecta Peme).

Budget Oncostellae: 99.931,41 €